Skip to main content
Download PDF
Download ePub

Cardioprotective role of royal jelly in the prevention of celecoxib-mediated cardiotoxicity in adult male albino rats

Journal of Cardiothoracic Surgery volume 19, Article number: 135 (2024) Cite this article

Abstract

Background

Celecoxib, a cyclooxygenase-2 selective inhibitor non-steroidal anti-inflammatory drugs, is used for the management of short- and long-term pain as well as in other inflammatory conditions. Unfortunately, its chronic use is highly associated with serious abnormal cardiovascular events. The current study was designed to explore the effect of long-term administration of celecoxib on the cardiac tissues of male albino rats. The study also examined the alleged cardioprotective effect of royal jelly.

Methods

Thirty, male albino rats were randomly divided into 3 equal groups; 10 each: (1) rats served as the control group and received no drug; (2) rats received celecoxib (50 mg/kg/day, orally), for 30 consecutive days; (3) rats received celecoxib (50 mg/kg/day, orally) plus royal jelly (300 mg/kg/day, orally) for 30 consecutive days. Sera were collected to assay cardiac enzymes and oxidant/antioxidant status. Rats were euthanatized and cardiac tissues were dissected for quantitative estimation of apoptotic genes (Bax) and anti-apoptotic gene (Bcl-2).

Results

Long-term celecoxib administration caused cardiotoxicity in male albino rats as manifested by significant elevation of serum levels of creatine phosphokinase (CPK), creatine kinase-MB (CK-MB), and lactate dehydrogenase (LDH), with ameliorative effects of royal jelly against celecoxib-induced cardiotoxicity as manifested by significantly decrease in serum CPK, CK-MB, and LDH levels. It also showed a significant decrease in the oxidative stress indicator malondialdehyde (MDA) levels and the bax gene. Additionally, it demonstrated significant increases in the bcl-2 gene and superoxide dismutase (SOD) levels, which contribute to its therapeutic effects against celecoxib-induced cardiotoxicity.

Conclusion

Long-term celecoxib administration caused cardiotoxicity in male albino rats with protective effect of royal jelly being given together. It could be concluded that royal jelly may prove a useful adjunct in patients being prescribed celecoxib.

Trial registration

Not applicable.

Peer Review reports

Background

Celecoxib, a cyclooxygenase-2 (COX-2) selective inhibitor, is a prospective alternative for the treatment of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis [1]. Following its introduction to the United States (US) market in December 1998 after FDA approval, celecoxib swiftly became one of the most often prescribed medications for the treatment of various forms of arthritis and the management of acute or chronic pain due to its favorable gastrointestinal toxicity profile [2].

The adverse effects of celecoxib, still require further in-depth study. The results of studies about the effect of celecoxib on the heart varied considerably. While one study proved the harmful effect of celecoxib on the heart in the form of an increased risk of myocardial infarction [3], another study confirmed that there was no noticeable effect on the heart [4]. Since 2004, when two COX-2-selective inhibitors, rofecoxib, and valdecoxib, were removed from the market due to an elevated risk of cardiovascular events, including myocardial infarction, celecoxib, as well as other selective and nonselective Non-steroidal anti-inflammatory drugs (NSAIDs), have been under intensive examination [5]. Celecoxib is the only powerful, selective COX-2 inhibitor (among the “coxib” family) that is still commercially accessible [6]. As a result, celecoxib became a commercial prototype inhibitor for the development of COX-2 enzyme anti-inflammatory medicines [7].

Royal jelly (RJ) is a nutrient-rich source of bioactive compounds that are essential to many biological processes. About (60–70% w/w) water, (9–18% w/w) proteins, (7–18% w/w) carbohydrates, and (3–8% w/w) lipids make up the majority of RJ. Minor components also found in RJ include vitamins (A, B complex, C, and E), Minerals (Fe, Zn, Mg, Mn, Ca, Na, K, and Cu), Amino acids (lysine, cysteine, glycine, proline, valine, serine, cysteine, alanine, tyrosine, threonine, leucine, isoleucine, glutamine, phenylalanine, hydroxyproline, aspartic acid, and glutamic acid), hormones, enzymes, nucleotides, polyphenols, and minor heterocyclic compounds [8]. RJ has potential health benefits, such as antimicrobial, antioxidant, anti-inflammatory, anticancer, antihyperlipidemic, cardio-protective, and hepatorenal-protective properties [9]. Free radical scavenging, suppression of oxidative and nitrosative stress, and anti-apoptotic ability are all thought to contribute to the cardioprotective effect of royal jelly [10,11,12].

With special concern for the cardioprotective effect of royal jelly administration, the current study was designed to explore the effect of long-term administration of celecoxib on cardiac tissues in male albino rats. In addition, to explore the effect of royal jelly on oxidant/antioxidant status regarding malondialdehyde (MDA), serum superoxide dismutase (SOD) and its effect on apoptotic genes (Bax) and anti-apoptotic gene (Bcl-2) expression.

Methods

Experimental animals

Thirty, apparently healthy, male albino rats weighing 200–230 g, randomly divided into three equal groups; each of 10 rats, were employed in this study. They were contained in clean cages with wire-bottomed galvanized metal walls. They were given a balanced diet and unlimited access to fresh tap water. Prior to commencement of the study, they had a 7-day acclimatization period.

Study design and setting

This study was conducted in the Lab animal unit, Pharmacology department, Faculty of Veterinary Medicine, Zagazig University, Zagazig, Egypt, in the period from March 2023 to May 2023. Zagazig University Scientific Research and Publications Ethics Committee approved the study. All steps and procedures in the study were carried out following Zagazig University Institutional Animal Care and Use Committee regulations, with approval No. ZU-IACUC/2/F/ 522 /2023.

Group 1(control group): rats received no drug. Rats of this group served as the control group. Group 2 (celecoxib group): rats received celecoxib (Pfizer Co., Egypt) (50 mg/kg/day, orally) [13], for 30 consecutive days, then rats were sacrificed and samples were collected. Group 3 (celecoxib + royal jelly group): rats received celecoxib (50 mg/kg/day, orally) [13], and royal jelly (Pharco Co., Egypt) (300 mg/kg/day, orally) [9] for 30 consecutive days, then rats were sacrificed and samples were collected.

Samples collection and preservation

Blood samples

Blood samples were collected using a 3 ml syringe directly from the ventricular puncture of rats into centrifuge tubes and left to clot for 15 min at room temperature then centrifuged at 3000 rpm for 10 min to allow serum separation, which was then aspirated into cryovials and stored at -20 °C for serum biochemical assays of cardiac enzymes and oxidant/antioxidant status.

Tissue specimens

Rats were euthanatized using sodium thiopental (200 mg/kg Bwt, I/P) for sampling. The cardiac tissues of each animal were dissected and cut into small pieces. About 30 mg of the rat cardiac tissue samples were immediately collected, transferred in liquid nitrogen, and kept at – 80 ◦C for total RNA extraction used for the determination of apoptotic and anti-apoptotic mRNA expression levels using RT-PCR [14].

Biochemical measurements in sera

Measurement of serum cardiac biomarkers concentrations

Quantitative estimation of serum creatine phosphokinase concentration (CPK), serum creatine kinase-myocardium bound concentration (CK-MB), and serum Lactate dehydrogenase concentration (LDH) were carried out automatically by Roche/Hitachi Cobas® c systems and Cobas® 6000 analyzer.

Oxidant/antioxidant status

Quantitative estimation of serum malondialdehyde (MDA), and serum superoxide dismutase (SOD) concentrations were carried out using commercially available kits supplied from Oxi Select™, USA [15].

Apoptotic and anti-apoptotic genes expression

TOPreal™ qPCR 2X PreMIX (SYBR Green with low ROX) (Cat. # P725, Enzynomics, Korea) was used for quantitative estimation of apoptotic genes (Bax) and anti-apoptotic gene (Bcl-2) based on the manufacturer’s protocol.

Gene expressions were measured using the below formula and Ct (2-ΔΔCt) (fold change) [14].

$$\begin{array}{l}{\bf{\Delta \Delta Ct}}\, = \,\left( {{\bf{C}}{{\bf{t}}_{{\bf{target}}}} - {\bf{C}}{{\bf{t}}_{{\bf{reference}}}}} \right)\,{\bf{test}}\,{\bf{sample}} - \\\left( {{\bf{C}}{{\bf{t}}_{{\bf{target}}}} - {\bf{C}}{{\bf{t}}_{{\bf{reference}}}}} \right)\,{\bf{control}}\,{\bf{sample}}\end{array}$$

Finally, considering the primer efficiency value of ~ 2, the gene expression level was determined as 1-ΔΔCt.

Statistical analysis

The obtained data were analyzed statistically using the Statistical Package for Social Sciences (SPSS) program (version 26.0; SPSS Inc, IL, USA) for Microsoft Windows®. One-way analysis of variance (ANOVA) was used to compare the means of the multiple groups. Tukey HSD post hoc analysis was used for in-between group comparisons. a P-value of less than 0.05 is considered to be significant.

Results

Biochemical measurements in sera

Effect on serum CPK, CK-MB, and LDH levels

Celecoxib administration (50 mg/kg/day, orally), for 30 successive days was claimed to cause cardiotoxicity in male albino rats as manifested by significant elevation (P < 0.05) of serum CPK, CK-MB, and LDH levels, with ameliorative effects of royal jelly against celecoxib-induced cardiotoxicity (Table 1).

Table 1 Effects of celecoxib administration (50 mg/kg/day, orally), and celecoxib plus royal jelly administration (300 mg/kg/day, orally) in comparison to the control group, on cardiac profile in male albino rats. Data are expressed as mean ± SD, n = 10/group
Full size table

Effect on serum MDA and SOD levels

Celecoxib administration (50 mg/kg/day, orally), for 30 successive days was claimed to cause oxidative stress in male albino rats as manifested by significant elevation of serum MDA and significant decline in SOD levels, with ameliorative effects of royal jelly against celecoxib-induced oxidative stress (Table 2).

Table 2 Effects of celecoxib administration (50 mg/kg/day, orally), and celecoxib plus royal jelly administration (300 mg/kg/day, orally) in comparison to the control group, on serum MDA and SOD in male albino rats. Data are expressed as mean ± SD, n = 10/group
Full size table

Apoptotic and anti-apoptotic genes expression

Celecoxib administration (50 mg/kg/day, orally), for 30 successive days was claimed to induce an apoptotic effect in male albino rats as manifested by a significant elevation of the serum apoptotic gene (Bax) and a significant decline in serum anti-apoptotic gene (Bcl-2) in liver, kidney, and heart with ameliorative effects of royal jelly against the celecoxib-induced apoptotic effect (Table 3).

Table 3 Effects of celecoxib administration (50 mg/kg/day, orally), and celecoxib plus royal jelly administration (300 mg/kg/day, orally) in comparison to the control group, on apoptotic and anti-apoptotic genes expression in male albino rats. Data are expressed as mean ± SD, n = 10/group
Full size table

Discussion

For over a century, nonsteroidal anti-inflammatory drugs (NSAIDs) have been among the most widely used treatments worldwide [16]. The anti-inflammatory drug celecoxib, the only inhibitor of cyclooxygenase-2 (COX-2 inhibitor) still used in the markets, for the treatment of various forms of arthritis and the management of acute or chronic pain due to its favorable gastrointestinal toxicity profile [17].

In our study, celecoxib administration (50 mg/kg/day, orally), for 30 successive days was claimed to cause cardiotoxicity in male albino rats with ameliorative effects of royal jelly against celecoxib-induced cardiotoxicity.

In fact, safety concerns, due to the elevated risk of myocardial infarction, caused all members of selective cyclooxygenase-2 (COX-2) inhibitors, except for celecoxib, to be withdrawn from the markets in 2004 to 2005 by the United States Food and Drug Administration (FDA) [18]. Celecoxib is still available on the market, nevertheless, as the FDA has determined its advantages outweigh any possible risks. Celecoxib has a significantly lower cardiovascular risk profile and the majority of research points to a low risk. The majority of early clinical studies using celecoxib in arthritic patients did not seem to indicate a rise in cardiovascular risk [19,20,21]. However, these trials tended to be short-term studies to evaluate pain management and the related adverse gastrointestinal events, with a relatively small proportion of patients at high cardiovascular risk or even excluded such patients entirely [22]. In a prospective, randomized, double-blind, multicenter, longer-term, placebo-controlled trial assessing the efficacy of celecoxib for the prevention of adenomatous polyps, celecoxib use was proved to be associated with a dose-related increase in cardiovascular harm (up to 3.4-fold) in form of myocardial infarction, stroke, heart failure, and even death [22].

A well-known diagnostic enzyme marker of myocardial damage is serum CPK, CK-MB, and LDH. Elevation of such cardiac markers indicates a significantly positive correlation between ischemic myocardial injury and inflammatory cell infiltration [23]. Following the WHO criteria for diagnosis of acute myocardial infarction (AMI), multiple cardiac biomarkers were used to diagnose acute myocardial infarction. Among such biomarkers are CPK, the oldest but non-cardiac specific marker, CK-MB as the most sensitive and specific marker for diagnosis of AMI, and cardiac reperfusion, and LDH, which is non-cardiac specific but the collaborated assays give an indication of myocardial damage [24]. Insufficient oxygen or glucose damages myocardial cells, tears heart membranes, or makes them permeable, which causes enzyme leakage and bloodstream entry [25] which indicates cardiotoxicity [26]. Rats exhibited increased serum cardiac enzyme levels of CPK, CK-MB, troponin-T, and LDH in return for celecoxib administration [27, 28].

The biochemical celecoxib-induced cardiotoxicity causes are surrounded by uncertainty. A widely accepted theory focuses on how celecoxib affects two important prostanoids, thromboxane A2 (TXA2) and prostacyclin (PGI2) which are essential for maintaining vascular homeostasis [29]. Thromboxane A2 is largely produced in platelets, which solely express COX-1 and promote platelet aggregation, vasoconstriction, and smooth-muscle proliferation. Prostacyclin, on the other hand, is the primary prostanoid product of endothelial cells and is produced as a result of COX-2 action. It has antiaggregative, antiproliferative, and vasodilatory properties [30]. Celecoxib may therefore suppress the vascular production of prostacyclin without affecting the synthesis of platelet-derived thromboxane A2. The imbalance between those two prostanoids leads to hypertension and atherosclerosis in a platelet-dependent mechanism creating a prothrombotic state [27]. Adenylyl cyclase (AC) enzyme is also inhibited by celecoxib, which leads to low levels of cyclic adenosine monophosphate (cAMP) [31]. The expression of thrombomodulin, a crucial inhibitor of blood coagulation, is downregulated in other platelet non-dependent pathways, which results in thrombosis [32]. Alternately, COX-2 suppression may cause a buildup of its substrate arachidonic acid, which results in the generation of harmful reactive oxygen species in the heart’s mitochondria [33]. Additionally, celecoxib eliminates the tissue factor (TF) expression attenuation caused by COX-2. The extrinsic coagulation pathway is vital for blood coagulation and thrombin production and is initiated by TF. As a result, TF is linked to thrombosis and cardiovascular system malfunction [34]. Respiratory chain enzyme (Complex IV) activity was significantly reduced following exposure to celecoxib. Parallel to this decline in complex IV activity, mitochondrial membrane potential (MMP) collapse, reactive oxygen species (ROS) production, mitochondrial swelling, ATP depletion, and lipid peroxidation occur [35].

In accordance with our findings, previous studies have demonstrated that elevated cardiac enzymes are usually reversible and will regain normal levels with time. In humans, CK-MB is detected in the serum 4 h after myocardial injury, peaks by 24 h, and normalizes within 48 to 72 h after myocardial ischemia, whereas the elevated CK levels may be detected for up to 60 h and then regain their baseline levels [36]. In rats, serum levels of CK-MB and LDH began to rise on day 1, reached their peak levels on day 7 after MI, and then declined gradually and normalized from day 21 onwards [37]. CK has a relatively short half-life (about 2–4 h), and thus activity rapidly returns to normal following cessation of myodegeneration or necrosis within a week [38].

The cardioprotective effect of royal jelly may be attributed to its efficient antioxidant and free radical scavenging capacity [39, 40]. Royal jelly (50, 100, and 150 mg/kg/orally, for 28 consecutive days) could remarkably reduce the paclitaxel-induced cardio-toxicity in adult male Wistar rats. It significantly reduced the cardiac biomarker creatine kinase (CK-BM) level and histopathological injuries such as diffused edema, hemorrhage, congestion, hyaline exudates, and necrosis. It also regained its total antioxidant capacity [10]. Royal jelly (250 mg/kg/orally, for 15 consecutive days) could significantly ameliorate the gamma radiation-induced cardio-toxicity in male albino rats. It remarkably regained normal serum-reduced glutathione (GSH) content, superoxide dismutase (SOD) activity, lipid peroxide [malondialdehyde (MDA)] levels, creatinine kinase-MB (CK-MB) levels, and cardiac troponin I level (cTnI). A somewhat normal appearance of cardiac muscle fibers was obtained thanks to RJ administration to radiation-exposed rats [11].

In our study, celecoxib administration (50 mg/kg/day, orally), for 30 successive days was claimed to cause oxidative stress in male albino rats as manifested by significant elevation of serum MDA and significant decline in SOD levels, with ameliorative effects of royal jelly against celecoxib-induced oxidative stress.

Oxidative stress (OS) is a shift in the balance between the production rate of oxidants and their elimination via the antioxidant defense system [41]. OS-mediated molecules are an array of metabolites derived from molecular reactive oxygen species (ROS) and reactive nitrogen species (RNS) [42]. Prime sites of ROS production in living organisms are the mitochondria, paroxysms, and endoplasmic reticulum. ROS are produced during the mitochondrial electron transport chain, through the oxidative phosphorylation pathway for ATP production [43]. ROS are also produced in phagocytes, auto-oxidation reactions, and subsequent to antioxidant enzymes (e.g., xanthine oxidase) [44]. RNS is derived from nitric oxide (•NO) metabolism [45]. ROS/RNS are produced from either endogenous or exogenous sources. Immune system activation, inflammation, mental stress, excessive exercise, cancer, infection, ischemia, and aging represent the endogenous stressors, while air pollution, water pollution, alcohol, cigarette smoke, heavy metals, pharmaceutical agents, and ultraviolet radiation act as exogenous sources of OS [46].

Antioxidants are the primary line of the body’s defense system against oxidative stress. In physiological conditions, antioxidants inhibit the oxidation reaction of molecules that can produce free radicals [47]. Several molecules play a role in such defense, either internally synthesized (endogenous), or externally supplied through foods (exogenous) antioxidants. Exogenous antioxidants, (Royal Jelly for instance), act as direct ROS scavengers and increase the antioxidant enzyme activities [48]. Endogenous antioxidant defenses involve a network of antioxidant enzymatic and non-enzymatic molecules that are usually disseminated within the cytoplasm and various cell organelles [49]. Primary antioxidant enzymes, such as superoxide dismutase (SOD), catalase, and several peroxidases catalyze a complex cascade of reactions to transform ROS into more stable molecules, such as water and O2. Malondialdehyde (MDA) is the end-product of polyunsaturated fatty acids oxidation in cellular membranes, thus it acts as a dependable marker of oxidative stress [50]. Non-enzymatic antioxidants include vitamins (A, C, E, and K), enzyme cofactors (Q10), and minerals (Zn, Mn, Cu, Se, etc.) [51].

In accordance with our findings, previous studies indicated an alteration in the oxidant/antioxidant status of rats treated with celecoxib [52,53,54,55]. The excessive generation of free radicals is considered one of the mechanisms by which celecoxib induces toxicity. Free radicals trigger the development of many diseases and cause harmful effects that cause the peroxidation of biomembranes and DNA, which is the reason for tissue destruction [56].

Several previous studies confirmed the concept of the beneficial and antioxidant effects of RJ [57,58,59]. Administration of royal jelly in vitro inhibited the production of pro-inflammatory cytokines such as TNF-α and IL-1, IL-6 in a dose-dependent manner [60]. Other in-vivo and in-vitro studies also proposed anti-inflammatory and anti-oxidant properties of royal jelly [61]. The Antioxidant activity of RJ can be attributed to the free radical scavengers; they can inhibit lipid peroxidation [62] via scavenging hydroxyl radicals [63], and they attributed this activity to three dipeptides containing tyrosine residues. Additionally, RJ inhibits the enzymes that elevate the peroxidation of endogenous lipids, as well as cytochrome P450 expression, which is one of the cellular sources of oxygen radicals [64].

In our study, celecoxib administration (50 mg/kg/day, orally), for 30 successive days was claimed to induce an apoptotic effect in male albino rats as manifested by a significant elevation of serum apoptotic gene (Bax) and a significant decline in serum anti-apoptotic gene (Bcl-2) in liver, kidney, and heart, with ameliorative effects of royal jelly against the celecoxib-induced apoptotic effect.

Apoptosis is programmed cell death, which involves the genetically determined elimination of cells. Since too little or too much cell death can result in pathology, such as autoimmune illnesses, neurodegeneration, or cancer, it is obvious that apoptosis needs to be strictly gene-regulated [65]. Several factors contributed to the apoptotic mechanism, among them, two main families of proteins including caspases and the Bcl-2 family. Caspases, death-driving cysteine proteases, play an effective role in the apoptotic process. Activation of caspases ensures that the cellular components are degraded in a controlled manner, carrying out cell death with minimal effect on surrounding tissues [66]. Whereas, Bcl-2, consists of anti-apoptotic and pro-apoptotic members. The anti-apoptotic members of this family, such as Bcl-2 and Bcl-XL, prevent apoptosis either by sequestering caspases or by preventing the release of mitochondrial apoptogenic factors such as cytochrome c and apoptosis-inducing factor (AIF) into the cytoplasm, which are responsible for caspases activation. In contrast, pro-apoptotic members of this family, such as Bax and Bak, trigger the release of caspases by inducing the release of mitochondrial apoptogenic factors into the cytoplasm leading to caspases activation [67].

Apoptosis is an essential physiological process for the selective elimination of individual cells without destruction or damage to the whole organ [68]. The morphological features of apoptosis include cell shrinkage and pyknosis, cytoplasmic and nuclear condensation, chromatin cleavage, apoptotic bodies formation, an intact plasma membrane, and exposure of surface molecules to phagocytosis [69]. In contrast, necrosis has been characterized as passive, accidental cell death that is triggered by external factors or disease with the uncontrolled release of inflammatory cells [70, 71]. The main morphological changes associated with necrosis include cell swelling, cytoplasmic vacuole formation, distended endoplasmic reticulum, cytoplasmic bleb formation, condensed, swollen, or ruptured mitochondria, disrupted organelle membranes, swollen and ruptured lysosomes, and ultimately disruption of the cell membrane [72]. While necrosis is always pathological and detrimental to an organ [65], apoptosis is a normal and physiological process to get rid of certain cells that have been damaged beyond repair. is almost always normal and advantageous. Additionally, apoptosis happens as a protective process, such as in immunological responses or when diseases or toxic chemicals destroy cells. Thus, it keeps normal tissue function [73].

In accordance with our findings, previous studies have confirmed celecoxib-induced apoptosis. Celecoxib causes apoptosis by causing the loss of the mitochondrial transmembrane potential, the release of cytochrome c and AIF, and the activation of caspase-9 and caspase-3. Additionally, the anti-apoptotic protein Bcl-2 was reduced in abundance whereas the pro-apoptotic protein Bax was enhanced by celecoxib. The data showed that mitochondria-dependent signaling, not PPAR/NF-B signaling, was the mechanism through which celecoxib triggered apoptosis in mouse liver cancer cells [74]. In another study, celecoxib induced apoptosis in 5-fluorouracil-resistant gastric cancer cells through protein kinase B (PKB) inhibition [75], which is a key component of the phosphatidyl-inositol-3 kinase (PI3K) intracellular pathway that exerts a pivotal role in regulating cell proliferation, survival, and metabolism [76]. Celecoxib induced apoptosis in glioblastoma tumor cells, the primary malignant tumor of the brain, via suppressing CIP2A/PP2A/Akt signaling axis [77].

Several previous studies confirmed the concept of the beneficial and anti-apoptotic effect of RJ against cisplatin-induced hepatorenal toxicity [78], nicotine-induced testicular injury in mice [79], doxorubicin-induced nephrotoxicity in male albino rats [80], and hydroxyurea-induced hepatic injury in rats [81]. Moreover, Royal jelly decreases the expression of the apoptotic gene (MMP-9) responsible for bladder cancer in humans [82].

More generally, this study highlights the necessity of better techniques for evaluating potential adverse cardiovascular outcomes of celecoxib, as well as the necessity of long-term, placebo-controlled trials to evaluate safety in addition to efficacy of royal jelly as a concomitant drug.

Conclusion

The study found that long-term administration of celecoxib caused cardiovascular complications in male albino rats. Royal jelly was found to significantly decrease serum levels of creatine phosphokinase (CPK), creatine kinase-MB (CK-MB), and lactate dehydrogenase (LDH). It also showed a significant decrease in the oxidative stress indicator malondialdehyde (MDA) levels and the bax gene. Additionally, it demonstrated significant increases in the bcl-2 gene and superoxide dismutase (SOD) levels, which contribute to its therapeutic effects against celecoxib-induced cardiotoxicity.

Data availability

All relevant data are included in this published article.

References

  1. Clemett D, Goa KL. Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain. Drugs. 2000;59:957–80.

    Article  CAS  PubMed  Google Scholar 

  2. McCormack PL. Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. Drugs. 2011;71:2457–89.

    Article  CAS  PubMed  Google Scholar 

  3. Caldwell B, Aldington S, Weatherall M, Shirtcliffe P, Beasley R. Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. J R Soc Med. 2006;99(3):132–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Puljak L, Marin A, Vrdoljak D, Markotic F, Utrobicic A, Tugwell P. Celecoxib for osteoarthritis. Cochrane Database Syst Reviews. 2017(5).

  5. Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Investig. 2006;116(1):4–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Cruz JV, Rosa JM, Kimani NM, Giuliatti S, dos Santos CB. The role of celecoxib as a potential inhibitor in the treatment of inflammatory diseases review. Curr Med Chem. 2022;29(17):3028–49.

    Article  CAS  PubMed  Google Scholar 

  7. Cryer B. The role of cyclooxygenase selective inhibitors in the gastrointestinal tract. Curr Gastroenterol Rep. 2003;5(6):453–8.

    Article  PubMed  Google Scholar 

  8. Ahmad S, Campos MG, Fratini F, Altaye SZ, Li J. New insights into the biological and pharmaceutical properties of royal jelly. Int J Mol Sci. 2020;21(2):382.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Mostafa RE, El-Marasy SA, Jaleel GA, Bakeer RM. Protective effect of royal jelly against diclofenac-induced hepato-renal damage and gastrointestinal ulcerations in rats. Heliyon. 2020; 6(2).

  10. Malekinejad H, Ahsan S, Delkhosh-Kasmaie F, Cheraghi H, Rezaei-Golmisheh A, Janbaz-Acyabar H. Cardioprotective effect of royal jelly on paclitaxel-induced cardio-toxicity in rats. Iran J Basic Med Sci. 2016;19(2):221.

    PubMed  PubMed Central  Google Scholar 

  11. Sarhan H, Naoum L. Protective role of royal jelly against gamma radiation-induced oxidative stress, cardio-toxicity, and organ dysfunctions in male rats. Egypt J Hosp Med. 2020;78(1):62–7.

    Article  Google Scholar 

  12. Sargazi M, Taghian F. Royal Jelly bioactive compounds and exercise improved cardiomyopathy and redox status in patients under methadone maintenance therapy: randomized clinical trial. J Herb Med. 2023;38:100634.

    Article  Google Scholar 

  13. Koçkaya EA, Selmanoğlu G, Kısmet K, Akay MT. Pathological and biochemical effects of therapeutic and supratherapeutic doses of celecoxib in Wistar albino male rats. Drug Chem Toxicol. 2010;33(4):410–4.

    Article  PubMed  Google Scholar 

  14. Eleawa SM, Alkhateeb MA, Alhashem FH, Bin-Jaliah I, Sakr HF, Elrefaey HM, et al. Resveratrol reverses cadmium chloride-induced testicular damage and subfertility by downregulating p53 and Bax and upregulating gonadotropins and Bcl-2 gene expression. J Reprod Dev. 2014;60(2):115–27.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Wang M, Utell MJ, Schneider A, Zareba W, Frampton MW, Oakes D, Hopke PK, Wiltshire J, Kane C, Peters A, Breitner S. Does total antioxidant capacity modify adverse cardiac responses associated with ambient ultrafine, accumulation mode, and fine particles in patients undergoing cardiac rehabilitation? Environ Res. 2016;149:15–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Montinari MR, Minelli S, De Caterina R. The first 3500 years of aspirin history from its roots–A concise summary. Vascul Pharmacol. 2019;113:1–8.

    Article  CAS  PubMed  Google Scholar 

  17. Maruyama R, Kiyohara Y, Kudo Y, Sugiyama T. Effects of the anti-inflammatory drug celecoxib on cell death signaling in human colon cancer. Naunyn Schmiedebergs Arch Pharmacol. 2023;24:1–5.

    Google Scholar 

  18. Andersohn F, Suissa S, Garbe E. Use of first-and second-generation cyclooxygenase-2–selective nonsteroidal anti-inflammatory drugs and risk of acute myocardial infarction. Circulation. 2006;113(16):1950–7.

    Article  CAS  PubMed  Google Scholar 

  19. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. JAMA. 2000;284(10):1247–55.

    Article  CAS  PubMed  Google Scholar 

  20. Solomon DH, Schneeweiss S, Glynn RJ, Kiyota Y, Levin R, Mogun H, Avorn J. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation. 2004;109(17):2068–73.

    Article  CAS  PubMed  Google Scholar 

  21. Farkouh ME, Kirshner H, Harrington RA, Ruland S, Verheugt FW, Schnitzer TJ, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the therapeutic Arthritis Research and gastrointestinal event trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet. 2004;364(9435):675–84.

    Article  CAS  PubMed  Google Scholar 

  22. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;352(11):1071–80.

    Article  CAS  PubMed  Google Scholar 

  23. Chen W, Liang J, Fu Y, Jin Y, Yan R, Chi J et al. Cardioprotection of cortistatin against isoproterenol-induced myocardial injury in rats. Annals Translational Med. 2020; 8(6).

  24. Antman E, Bassand JP, Klein W, Ohman M, Lopez Sendon JL, Rydén L, et al. Myocardial infarction redefined—a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction: the Joint European Society of Cardiology/American College of Cardiology Committee. J Am Coll Cardiol. 2000;36(3):959–69.

    Article  PubMed  Google Scholar 

  25. Farvin KS, Anandan R, Kumar SH, Shiny KS, Sankar TV, Thankappan TK. Effect of squalene on tissue defense system in isoproterenol-induced myocardial infarction in rats. Pharmacol Res. 2004;50(3):231–6.

    Article  CAS  Google Scholar 

  26. Ahmad S, Panda BP, Kohli K, Fahim M, Dubey K. Folic acid ameliorates celecoxib cardiotoxicity in a doxorubicin heart failure rat model. Pharm Biol. 2017;55(1):1295–303.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Mosaad SM, Zaitone SA, Ibrahim A, El-Baz AA, Abo-Elmatty DM, Moustafa YM. Celecoxib aggravates cardiac apoptosis in L-NAME-induced pressure overload model in rats: immunohistochemical determination of cardiac caspase-3, Mcl-1, Bax and Bcl-2. Chemico-Biol Interact. 2017;272:92–106.

    Article  CAS  Google Scholar 

  28. Ahmad S, Panda BP, Fahim M, Dhyani N, Dubey K. Ameliorative effect of beraprost sodium on celecoxib induced cardiotoxicity in rats. Iran J Pharm Research: IJPR. 2018;17(1):155.

    CAS  PubMed  PubMed Central  Google Scholar 

  29. FitzGerald GA. COX-2 and beyond approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discovery. 2003;2(11):879–90.

    Article  CAS  PubMed  Google Scholar 

  30. FitzGerald GA. Coxibs and cardiovascular disease. N Engl J Med. 2004;351(17):1709–11.

    Article  CAS  PubMed  Google Scholar 

  31. Saini SS, Gessell-Lee DL, Peterson JW. The cox-2-specific inhibitor celecoxib inhibits adenylyl cyclase. Inflammation. 2003;27:79–88.

    Article  CAS  PubMed  Google Scholar 

  32. Rabausch K, Bretschneider E, Sarbia M, Meyer-Kirchrath J, Censarek P, Pape R, Fischer JW, Schrör K, Weber AA. Regulation of thrombomodulin expression in human vascular smooth muscle cells by COX-2–derived prostaglandins. Circul Res. 2005;96(1):e1–6.

    Article  CAS  Google Scholar 

  33. Fosslien E. Cardiovascular complications of non-steroidal anti-inflammatory drugs. Annals Clin Lab Sci. 2005;35(4):347–85.

    CAS  Google Scholar 

  34. Chu AJ. Tissue factor upregulation drives a thrombosis–inflammation circuit in relation to cardiovascular complications. Cell biochemistry and function: Cellular biochemistry and its modulation by active agents or disease. 2006; 24(2):173–92.

  35. Atashbar S, Jamali Z, Khezri S, Salimi A. Celecoxib decreases mitochondrial complex IV activity and induces oxidative stress in isolated rat heart mitochondria: an analysis for its cardiotoxic adverse effect. J Biochem Mol Toxicol. 2022;36(1):e22934.

    Article  CAS  PubMed  Google Scholar 

  36. Mair J, Artner-Dworzak E, Lechleitner P, Morass B, Smidt J. Wagner iet al. Early diagnosis of acute myocardial infarction by a newly developed rapid immunoturbidimetric assay for myoglobin. Heart. 1992;68(11):462–8.

    Article  CAS  Google Scholar 

  37. Srikanth G, Prakash P, Tripathy N, Dikshit M, Nityanand S. Establishment of a rat model of myocardial infarction with a high survival rate: a suitable model for evaluation of efficacy of stem cell therapy. J Stem Cells Regenerative Med. 2009;5(1):30.

    Article  CAS  Google Scholar 

  38. Goicoechea M, Cía F, José CS, Asensio A, Emparanza JI, Gil AG, et al. Minimizing creatine kinase variability in rats for neuromuscular research purposes. Lab Anim. 2008;42(1):19–25.

    Article  CAS  PubMed  Google Scholar 

  39. Silici S, Ekmekcioglu O, Kanbur M, Deniz K. The protective effect of royal jelly against cisplatin-induced renal oxidative stress in rats. World J Urol. 2011;29:127–32.

    Article  PubMed  Google Scholar 

  40. Olas B. Bee products as interesting natural agents for the prevention and treatment of common cardiovascular diseases. Nutrients. 2022;14(11):2267.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Trevisan M, Browne R, Ram M, Muti P, Freudenheim J, Carosella AM, et al. Correlates of markers of oxidative status in the general population. Am J Epidemiol. 2001;154(4):348–56.

    Article  CAS  PubMed  Google Scholar 

  42. Bernabucci U, Ronchi B, Lacetera N, Nardone A. Markers of oxidative status in plasma and erythrocytes of transition dairy cows during hot season. J Dairy Sci. 2002;85(9):2173–9.

    Article  CAS  PubMed  Google Scholar 

  43. Rao PS, Kalva S, Yerramilli A, Mamidi S. Free radicals and tissue damage: role of antioxidants. Free Radicals Antioxid. 2011;1(4):2–7.

    Article  CAS  Google Scholar 

  44. Dupré-Crochet S, Erard M, Nüβe O. ROS production in phagocytes: why, when, and where? J Leukoc Biol. 2013;94(4):657–70.

    Article  PubMed  Google Scholar 

  45. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol. 2007;39(1):44–84.

    Article  CAS  PubMed  Google Scholar 

  46. Pham-Huy LA, He H, Pham-Huy C. Free radicals, antioxidants in disease and health. Int J Biomedical Science: IJBS. 2008;4(2):89–96.

    Article  CAS  Google Scholar 

  47. David AV, Arulmoli R, Parasuraman S. Overviews of biological importance of quercetin: a bioactive flavonoid. Pharmacogn Rev. 2016;10(20):84–6.

    Article  CAS  Google Scholar 

  48. Ďuračková Z. Some current insights into oxidative stress. Physiol Res. 2010;59(4):459–69.

    Article  PubMed  Google Scholar 

  49. Reiter RJ, Paredes SD, Manchester LC, Tan DX. Reducing oxidative/nitrosative stress: a newly-discovered genre for melatonin. Crit Rev Biochem Mol Biol. 2009;44(4):175–200.

    Article  CAS  PubMed  Google Scholar 

  50. Ziech D, Franco R, Georgakilas AG, Georgakila S, Malamou-Mitsi V, Schoneveld O, et al. The role of reactive oxygen species and oxidative stress in environmental carcinogenesis and biomarker development. Chemico-Biol Interact. 2010;188(2):334–9.

    Article  CAS  Google Scholar 

  51. Mirończuk-Chodakowska I, Witkowska AM, Zujko ME. Endogenous non-enzymatic antioxidants in the human body. Adv Med Sci. 2018;63(1):68–78.

    Article  PubMed  Google Scholar 

  52. Burak Cimen MY, Bölgen Cimen Ö, Eskandari G, Sahin G, Erdoğan C, Atik U. In vivo effects of meloxicam, celecoxib, and ibuprofen on free radical metabolism in human erythrocytes. Drug Chem Toxicol. 2003;26(3):169–76.

    Article  CAS  PubMed  Google Scholar 

  53. Ozgocmen S, Ardicoglu O, Erdogan H, Fadillioglu E, Gudul H. In vivo effect of celecoxib and tenoxicam on oxidant/anti-oxidant status of patients with knee osteoarthritis. Annals Clin Lab Sci. 2005;35(2):137–43.

    CAS  Google Scholar 

  54. Sozer S, Diniz G, Lermioglu F. Effects of celecoxib in young rats: histopathological changes in tissues and alterations of oxidative stress/antioxidant defense system. Arch Pharm Res. 2011;34:253–9.

    Article  CAS  PubMed  Google Scholar 

  55. Melekh B, Ilkiv I, Lozynskyi A, Sklyarov A. Antioxidant enzyme activity and lipid peroxidation in rat liver exposed to celecoxib and lansoprazole under epinephrine-induced stress. J Appl Pharm Sci. 2017;7(10):094–9.

    CAS  Google Scholar 

  56. Hamza RZ, Al-Eisa RA, El-Shenawy NS. Possible ameliorative effects of the royal jelly on hepatotoxicity and oxidative stress induced by molybdenum nanoparticles and/or cadmium chloride in male rats. Biology. 2022;11(3):450.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Cotter TG, Rinella M. Nonalcoholic fatty liver disease 2020: the state of the disease. Gastroenterology. 2020;158(7):1851–64.

    Article  CAS  PubMed  Google Scholar 

  58. You MM, Liu YC, Chen YF, Pan YM, Miao ZN, Shi YZ, Si JJ, Chen ML, Hu FL. Royal jelly attenuates nonalcoholic fatty liver disease by inhibiting oxidative stress and regulating the expression of circadian genes in ovariectomized rats. J Food Biochem. 2020;44(3):e13138.

    Article  PubMed  Google Scholar 

  59. Karimi E, Khorvash F, Arab A, Sepidarkish M, Saadatnia M, Amani R. The effects of royal jelly supplementation on oxidative stress, inflammatory mediators, mental health, cognitive function, quality of life, and clinical outcomes of patients with ischemic stroke: study protocol for a randomized controlled trial. BMC Nutr. 2023;9(1):1–8.

    Article  Google Scholar 

  60. Kohno K, Okamoto I, Sano O, Arai N, Iwaki K, Ikeda M, Kurimoto M. Royal jelly inhibits the production of proinflammatory cytokines by activated macrophages. Biosci Biotechnol Biochem. 2004;68(1):138–45.

    Article  CAS  PubMed  Google Scholar 

  61. Aslan Z, Aksoy L. Anti-inflammatory effects of royal jelly on ethylene glycol induced renal inflammation in rats. Int Brazilian J Urol. 2015;41:1008–13.

    Article  Google Scholar 

  62. Hadi A, Najafgholizadeh A, Aydenlu ES, Shafiei Z, Pirivand F, Golpour S, et al. Royal jelly is an effective and relatively safe alternative approach to blood lipid modulation: a meta-analysis. J Funct Foods. 2018;41:202–9.

    Article  CAS  Google Scholar 

  63. Maleki V, Jafari-Vayghan H, Saleh-Ghadimi S, Adibian M, Kheirouri S, Alizadeh M. Effects of Royal jelly on metabolic variables in diabetes mellitus: a systematic review. Complement Ther Med. 2019;43:20–7.

    Article  PubMed  Google Scholar 

  64. Kanbur M, Eraslan G, Silici S, Karabacak M. Effects of sodium fluoride exposure on some biochemical parameters in mice: evaluation of the ameliorative effect of royal jelly applications on these parameters. Food Chem Toxicol. 2009;47(6):1184–9.

    Article  CAS  PubMed  Google Scholar 

  65. Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007;35(4):495–516.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Rathore S, Datta G, Kaur I, Malhotra P, Mohmmed A. Disruption of cellular homeostasis induces organelle stress and triggers apoptosis-like cell-death pathways in malaria parasite. Cell Death Dis. 2015;6(7):e1803.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Hussar P. Apoptosis regulators bcl-2 and caspase-3. Encyclopedia. 2022;2(4):1624–36.

    Article  Google Scholar 

  68. Lockshin RA, Zakeri Z. Programmed cell death and apoptosis: origins of the theory. Nat Rev Mol Cell Biol. 2001;2(7):545–450.

    Article  CAS  PubMed  Google Scholar 

  69. Blagosklonny MV. Cell death beyond apoptosis. Leukemia. 2000;14(8):1502–8.

    Article  CAS  PubMed  Google Scholar 

  70. Fink SL, Cookson BT. Apoptosis, pyroptosis, and necrosis: mechanistic description of dead and dying eukaryotic cells. Infect Immun. 2005;73(4):1907–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Xu X, Lai Y, Hua ZC. Apoptosis and apoptotic body: disease message and therapeutic target potentials. Biosci Rep. 2019;39(1):BSR20180992.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. D’arcy MS. Cell death: a review of the major forms of apoptosis, necrosis and autophagy. Cell Biol Int. 2019;43(6):582–92.

    Article  PubMed  Google Scholar 

  73. Chi H, Chang HY, Sang TK. Neuronal cell death mechanisms in major neurodegenerative diseases. Int J Mol Sci. 2018;19(10):3082.

    Article  PubMed  PubMed Central  Google Scholar 

  74. Shao D, Kan M, Qiao P, Pan Y, Wang Z, Xiao X, Li J, Chen L. Celecoxib induces apoptosis via a mitochondria-dependent pathway in the H22 mouse hepatoma cell line. Mol Med Rep. 2014;10(4):2093–8.

    Article  CAS  PubMed  Google Scholar 

  75. Choi SM, Cho YS, Park G, Lee SK, Chun KS. Celecoxib induces apoptosis through akt inhibition in 5-fluorouracil-resistant gastric cancer cells. Toxicol Res. 2021;37:25–33.

    Article  CAS  PubMed  Google Scholar 

  76. Manning BD, Toker A. AKT/PKB signaling: navigating the network. Cell. 2017;169(3):381–405.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Gao D, Nyalali AM, Hou Y, Xu Y, Zhou J, Zhao W, Huang B, Li F. 2, 5-Dimethyl celecoxib inhibits proliferation and cell cycle and induces apoptosis in glioblastoma by suppressing CIP2A/PP2A/Akt signaling Axis. J Mol Neurosci. 2021;1:1–11.

    Google Scholar 

  78. Karadeniz A, Simsek N, Karakus E, Yildirim S, Kara A, Can I, Kisa F, Emre H, Turkeli M. Royal jelly modulates oxidative stress and apoptosis in liver and kidneys of rats treated with cisplatin. Oxidative medicine and cellular longevity. 2011; 2011.

  79. Azad F, Nejati V, Shalizar-Jalali A, Najafi G, Rahmani F. Antioxidant and anti‐apoptotic effects of royal jelly against nicotine‐induced testicular injury in mice. Environ Toxicol. 2019;34(6):708–18.

    Article  CAS  PubMed  Google Scholar 

  80. Mohamed HK, Mobasher MA, Ebiya RA, Hassen MT, Hagag HM, El-Sayed R, et al. Anti-inflammatory, anti-apoptotic, and antioxidant roles of honey, royal jelly, and propolis in suppressing nephrotoxicity induced by doxorubicin in male albino rats. Antioxidants. 2022;11(5):1029.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Tohamy HG, El-Neweshy MS, Soliman MM, Sayed S, Shukry M, Ghamry HI, Abd-Ellatieff H. Protective potential of royal jelly against hydroxyurea-induced hepatic injury in rats via antioxidant, anti-inflammatory, and anti-apoptosis properties. PLoS ONE. 2022;17(3):e0265261.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Fazili N, Soheili ZS, Malekzadeh-Shafaroudi S, Samiei S, D Alipoor S, Moshtaghi N, et al. Royal Jelly decreases MMP-9 expression and induces apoptosis in human bladder Cancer 5637 cells. J Cell Mol Res. 2021;13(1):36–43.

    CAS  Google Scholar 

Download references

Acknowledgements

None.

Funding

Not applicable.

Open access funding provided by The Science, Technology & Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB).

Author information

Authors and Affiliations

  1. Department of Pharmacology, Faculty of Vet. Med, Zagazig University, Zagazig, 43511, Egypt

    Naglaa Z. H. Eleiwa, Hesham A. M. I. Khalifa & Heba A. Nazim

Authors
  1. Naglaa Z. H. Eleiwa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hesham A. M. I. Khalifa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Heba A. Nazim
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors contributed to the creation of the manuscript.

Corresponding author

Correspondence to Heba A. Nazim.

Ethics declarations

Ethics approval and consent to participate

Ethics Approval Committee: Zagazig University Scientific Research and Publications Ethics Committee approved the study.

Consent to participate

All steps and procedures in the study were carried out following Zagazig University Institutional Animal Care and Use Committee regulations, with approval No. ZU-IACUC/2/F/ 522 /2023.

It is declared that

All methods were carried out in accordance with relevant guidelines and regulations. It was performed according to the recommendations of Good Clinical Practice and the Declaration of Helsinki (2013).

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Eleiwa, N.Z.H., Khalifa, H.A.M.I. & Nazim, H.A. Cardioprotective role of royal jelly in the prevention of celecoxib-mediated cardiotoxicity in adult male albino rats. J Cardiothorac Surg 19, 135 (2024). https://doi.org/10.1186/s13019-024-02593-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s13019-024-02593-2

Keywords

Journal of Cardiothoracic Surgery

ISSN: 1749-8090

Contact us